Clareo Health | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All participants with or without diabetes:
Have a Body Mass Index (BMI) ≥27 kilogram/square meter (kg/m²) at screening
Diagnosed with chronic kidney disease (CKD)
Has an estimated glomerular filtration rate (eGFR) ≥25 to ≤60 ml/min/1.73 m² or eGFR ≥25 to ≤75 ml/min/1.73 m² if urine albumin-to-creatinine ratio (UACR) \>30 milligram/gram (mg/g)
Have been receiving an angiotensin-converting enzyme (ACE) or angiotensin II receptor blockers (ARB) that is considered the maximal appropriate dose by the investigator for treatment of chronic kidney disease or hypertension (unless the participant has low blood pressure or hypotension)
Participants without diabetes:
Have Hemoglobin A1c (HbA1c) \<6.5% at screening
Participants with Type 2 diabetes:
Have been diagnosed at least 180 days prior to screening
Have HbA1c ≤9.5% at screening
You may not be if
All participants:
Have a self-reported change in body weight \>5 kilogram (kg) within 90 days prior to screening.
Have a prior or planned surgical treatment for obesity
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 180 days
Have eGFR \<25 mL/min/1.73m² calculated by using creatinine-based chronic kidney disease epidemiology collaboration (CKD-EPI) equations, as determined by central laboratory at screening.
Have a history of unstable or rapidly progressing renal disease according to investigator judgment
Have a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility)
Have had a history of chronic or acute pancreatitis
Participants with T2D:
Have history of proliferative diabetic retinopathy or diabetic macular edema or non-proliferative diabetic retinopathy that requires acute treatment.
Have been diagnosed with type 1 diabetes (T1D) or have history of ketoacidosis or hyperosmolar state/coma
